While recent advances in gene therapy have offered unprecedented options for patients with hemophilia, new data presented at ...

Eight years after Novartis AG gained U.S. FDA approval of the first CAR T therapy, Kymriah (tisagenlecleucel), for B-cell acute lymphoblastic leukemia, developers are advancing prospects that could ...

Pulse Biosciences Inc. presented late-breaking results from its successful first-in-human study of its nanosecond pulsed field ablation technology in treating atrial fibrillation at the 39th European ...

A new study aimed to investigate the therapeutic effect of ISM012-042 in a chronic T-cell transfer-induced colitis model in mice that mimicked Crohn’s disease.

Japan’s investor community is ramping up both inbound and outbound investment to create a cross-border fertile hub of ...

Total biopharma financings reached $18.69 billion in the third quarter (Q3) of 2025, rising 14% from $16.41 billion in Q2 and ...

The International Medical Device Regulators Forum (IMDRF) has issued a draft guidance for predetermined change control plans ...

Confo Therapeutics NV has secured a 2-year €1 million (US$1.2 million) grant from Flanders Innovation & Entrepreneurship ...

Boehringer Ingelheim Pharma GmbH & Co KG has signed an asset purchase agreement with Accent Therapeutics Inc. for Accent’s ...

A yearslong bipartisan effort to end the patent-eligibility chaos the U.S. Supreme Court created more than a decade ago could finally come to fruition with the current Congress.

Biopharma happenings, including deals and partnerships, and other news in brief: Accent, Apotex, Benchsci, Boehringer Ingelheim, Catalent, Citius, Evaxion, Klotho, Lisata, Nasus, Sanofi, Searchlight, ...

An uncommon route to the public markets – direct listing – paid off for Turn Therapeutics Inc., with shares (NASDAQ:TTRX) closing Oct. 9 at $9.20, up $2.20, or 31%, having risen as high as $26.50 in ...